|
Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma |
Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau J-L, Woronoff-Lemsi M-C |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau J-L, Woronoff-Lemsi M-C. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. PharmacoEconomics 2009; 27(1): 55-68 Indexing Status Subject indexing assigned by NLM MeSH Adult; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Combined Modality Therapy /economics; Cost-Benefit Analysis; Cyclophosphamide /economics /therapeutic use; Doxorubicin /economics /therapeutic use; Female; Humans; Lymphoma, Non-Hodgkin /economics /therapy; Male; Peripheral Blood Stem Cell Transplantation /economics; Prednisolone /economics /therapeutic use; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous /economics; Vincristine /economics /therapeutic use AccessionNumber 22009100904 Date bibliographic record published 02/12/2009 |
|
|
|